Cargando…
SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review
AIM OF THE STUDY: To evaluate the efficacy of sodium/glucose cotransporter-2 inhibitors (SGLT2i) in improving hepatic fibrosis and steatosis of non-alcoholic fatty liver disease (NAFLD) patients with type 2 diabetes mellitus (T2DM). MATERIAL AND METHODS: We searched CENTRAL, MEDLINE, and EMBASE and...
Autores principales: | Dwinata, Michael, Putera, David Dwi, Hasan, Irsan, Raharjo, Monica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816633/ https://www.ncbi.nlm.nih.gov/pubmed/33511282 http://dx.doi.org/10.5114/ceh.2020.102173 |
Ejemplares similares
-
Carvedilol vs endoscopic variceal ligation for primary and secondary prevention of variceal bleeding: Systematic review and meta-analysis
por: Dwinata, Michael, et al.
Publicado: (2019) -
Correlation of gut Firmicutes/Bacteroidetes ratio with fibrosis and steatosis
stratified by body mass index in patients with non-alcoholic fatty liver
disease
por: JASIRWAN, Chyntia Olivia Maurine, et al.
Publicado: (2020) -
Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis
por: Zhou, Peipei, et al.
Publicado: (2023) -
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan
por: Tuong, Tran Thi Khanh, et al.
Publicado: (2020) -
Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease
por: Ayoub, Fares, et al.
Publicado: (2018)